Debra Silberg
Director/Miembro de la Junta en Ellodi Pharmaceuticals .
Perfil
Debra Silberg is currently working as a Director at Ellodi Pharmaceuticals since 2023.
Prior to this, she worked as VP-Clinical Development at Shire Plc and as Chief Medical Officer at Finch Therapeutics Group, Inc. She completed her undergraduate degree from the University of Michigan and holds a doctorate degree from D'Amore-Mckim School of Business and The Wayne State University School of Medicine.
Cargos activos de Debra Silberg
| Empresas | Cargo | Inicio |
|---|---|---|
Ellodi Pharmaceuticals
 Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | Director/Miembro de la Junta | 27/02/2023 |
Antiguos cargos conocidos de Debra Silberg.
| Empresas | Cargo | Fin |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Director Técnico/Científico/I+D | - |
| SHIRE | Corporate Officer/Principal | - |
Formación de Debra Silberg.
| University of Michigan | Undergraduate Degree |
| D'Amore-Mckim School of Business | Doctorate Degree |
| The Wayne State University School of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Empresas privadas | 2 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Ellodi Pharmaceuticals
Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | Health Technology |
- Bolsa de valores
- Insiders
- Debra Silberg
